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ABSTRACT
Myelodysplastic syndromes (MDS) are a diverse group of malignant clonal 
hematopoietic stem cell disorders characterized by ineffective hematopoiesis, 
dysplastic cell morphology in one or more hematopoietic lineages, and a risk of 
progression to acute myeloid leukemia (AML). Approximately 50% of MDS patients 
respond to current FDA-approved drug therapies but a majority of responders 
relapse within 2-3 years. There is therefore a compelling need to identify potential 
new therapies for MDS treatment. We utilized the MDS-L cell line to investigate 
the anticancer potential and mechanisms of action of a plant-derived compound, 
Withaferin A (WFA), in MDS. WFA was potently cytotoxic to MDS-L cells but had 
no significant effect on the viability of normal human primary bone marrow cells. 
WFA also significantly reduced engraftment of MDS-L cells in a xenotransplantation 
model. Through transcriptome analysis, we identified reactive oxygen species (ROS)-
activated JNK/AP-1 signaling as a major pathway mediating apoptosis of MDS-L cells 
by WFA. We conclude that the molecular mechanism mediating selective cytotoxicity 
of WFA on MDS-L cells is strongly associated with induction of ROS. Therefore, 
pharmacologic manipulation of redox biology could be exploited as a selective 
therapeutic target in MDS.
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INTRODUCTION
Myelodysplastic syndromes (MDS) are a diverse 
group of malignant clonal hematopoietic stem cell 
disorders characterized by ineffective hematopoiesis, 
dysplastic cell morphology in one or more hematopoietic 
lineages, and a risk of progression to acute myeloid 
leukemia (AML) [1, 2]. Ineffective hematopoiesis 
manifests clinically as cytopenias – anemia being the 
most common, bleeding and recurrent infections [1, 3]. 
Approximately 30% of MDS patients progress to AML 
while progressive disease in the other 70% culminates 
in complete bone marrow failure [4]. About 15% of 
MDS cases occur as a late complication of exposure to 
cytotoxic therapy and are classified as therapy-related 
MDS (t-MDS) [1]. MDS are generally thought of as 
diseases of the elderly, with a median age at diagnosis 
of 65-70 years [1]. However, the age of diagnosis for 
t-MDS correlates with the age of cytotoxic therapy 
treatment [5].
MDS is incurable with current FDA-approved drug 
therapies (azacitidine, decitabine and lenalidomide). 
Approximately 50% of MDS patients respond to these 
therapies and a majority of responders relapse within 2-3 
years [6–8]. Patient outcomes after drug therapy failure 
are very poor with median overall survival and 2-year 
survival probability of 5.6 months and 15%, respectively 
[8–10]. Hematopoietic stem cell transplantation (HSCT) 
is potentially curative but comorbidities and treatment-
related morbidity and mortality in older patients limits its 
use; less than 10% of MDS patients are referred to HSCT 
[11]. Given the current status of MDS treatment, there is a 
compelling need to investigate potential new therapies for 
MDS treatment.
Scientific exploration of plant-derived compounds 
for cancer treatment is increasing because they are 
thought to be less toxic than current chemotherapy and 
radiotherapy regimens [12]. Withaferin A (WFA) is a 
plant-derived steroidal lactone isolated from Withania 
somnifera (also known as Indian Ginseng, Indian Winter 
cherry or Ashwagandha) with demonstrated anticancer 
activities in several cancer models including prostate, 
breast, cervical and pancreatic cancers, as well as 
melanoma and lymphoma [13–15].
The heterogeneity of MDS has made it difficult to 
generate a mouse that models complete disease phenotype, 
and xenotransplantation of patient bone marrow cells into 
immunocompromised mice is poor and highly inefficient 
[16, 17]. We utilized the validated human MDS-L cell 
line, which has been used to successfully establish a MDS 
xenograft model [18–20], to determine if the anticancer 
effects of WFA extend to MDS. Our data demonstrate 
that WFA induces selective cytotoxicity of MDS-L cells 
while sparing normal bone marrow cells both in vitro and 
in vivo. Biochemical studies identified reactive oxygen 
species (ROS) induced JNK/AP-1 apoptotic cell death as 
a major pathway by which WFA causes cytotoxicity in 
MDS-L cells.
RESULTS
WFA has a potent but selective anti-proliferative 
effect on MDS-L cells in vitro and in vivo
The MDS-L cell line is not only a validated in 
vitro model for MDS but is also representative of highly 
aggressive disease, displaying deletions in chromosomes 
5 and 7 [18, 19]. These deletions are the most common 
cytogenetic abnormalities observed in MDS and are 
associated with significantly worse prognosis [21–23]. 
Initial studies showed that WFA inhibited in vitro 
proliferation of MDS-L cells in a dose dependent manner 
(Figure 1A), with an IC50 in the 6-9μM range. The decrease 
in MDS-L cell proliferation by WFA was accompanied 
by a decrease in cell viability (Figure 1A), which was 
also dose-dependent. Lenalidomide (LENA) is the FDA-
approved treatment for MDS subjects harboring a deletion 
in chromosome 5q (del (5q)) [24]. Since MDS-L cells 
have a deletion in chromosome 5 [19], we assessed the 
relative efficacy of WFA in comparison to LENA. Notably, 
WFA was substantially more effective than LENA in 
inhibiting MDS-L cell proliferation in vitro (Figure 1B). 
The modest cytotoxicity of LENA on MDS-L cells we 
observed (Figure 1B) was in contrast to reported studies 
[19]. Therefore, we replicated the reported cytotoxic 
effects of LENA on MDS-L cells [19] by showing that 
LENA treatment every 24 h inhibited MDS-L proliferation 
(Supplementary Figure 1A). Although LENA caused some 
cell death over time (cell viability dropped from 90% to 
50% by day 9) (Supplementary Figure 1B), the number of 
cells recovered at each time point was the same or slightly 
higher than the number seeded. These observations 
suggested that LENA had more of a cytostatic effect 
on MDS-L cells compared to WFA, which was more 
cytotoxic.
The clinical relevance of the MDS-L data was 
validated by showing that WFA induced apoptotic cell 
death of human primary bone marrow cells from MDS 
patients (Figure 1C). Control experiments with normal 
human primary bone marrow cells showed no appreciable 
toxicity at all the doses tested (Figure 1C), demonstrating 
that the cytotoxic effects of WFA are selective to 
malignant MDS cells.
We utilized the MDS-L NSG-hSCF/hGM-CSF/
hIL3 (NSGS) xenograft model [20] to investigate the 
anti-MDS effect of WFA in vivo by comparing MDS-L 
bone marrow engraftment in vehicle versus WFA-
treated mice (Supplementary Figure 2A, 2B). WFA (8 
mg/kg) significantly reduced bone marrow engraftment 
of MDS-L cells in NSGS mice compared to the vehicle 
treatment (Figure 2A, 2B). Immunohistochemical 
examination of sample bone marrow tissues confirmed 
Oncotarget77438www.impactjournals.com/oncotarget
Figure 1: WFA selectively suppresses survival of MDS-L and human primary MDS patient bone marrow cells in vitro. 
(A) MDS-L cells were treated with increasing concentrations of WFA for 48 h and cell viability was measured by MTT assay (left) or trypan 
blue exclusion (right). Data are presented as mean ± SD of triplicate cultures. Results from one (n>3) of similar experiments are shown. 
(B) MDS-L cells were treated with increasing concentrations of WFA or LENA for 48 h and cell viability was determined by MTT assay. 
Presented data are mean ± SD of triplicate cultures and are representative of three independent experiments. (C) Human primary MDS 
patient bone marrow samples were treated with varying concentrations of WFA for 24 h and cell viability was assessed by annexin-V/PI 
assay (left). Cell viability of normal human primary bone marrow cells treated with WFA for 48 h was measured by MTT assay (right). 
Presented are mean ± SD of triplicate cultures and are representative of two independent experiments. ** = p<0.005, *** = p<0.0005 
indicates statistically significant differences between treated and control values.
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a more prominent uniform infiltrate of cells with 
displacement of the normal hematopoietic cell 
population in vehicle-treated engrafted mice, but WFA 
treatment restored the marrow of engrafted mice to 
a more normal appearance, with all hematopoietic 
components in varying stages of maturation (Figure 2C). 
Remarkably, WFA treatment did not cause any apparent 
bone marrow suppression of endogenous mouse stem 
cells (Supplementary Figure 2C). This is of particular 
importance because chemotherapeutic drugs generally 
cause bone marrow suppression, which leads to treatment 
delays and significant dose reductions [25]. These 
experiments indicate that WFA has an anti-proliferative 
effect on MDS-L cells both in vitro and in vivo without 
exerting non-specific toxicity to normal cells.
WFA induced apoptosis of MDS-L cells
NF-κB has been implicated in hematologic 
malignancies and is a suggested potential therapeutic 
target in MDS [26]. Despite reported ability of WFA to 
target NF-kB in lymphoma models [14], microscopy 
analyses revealed WFA treatment did not alter subcellular 
distribution of NF-κB in MDS-L cells (Supplementary 
Figure 3A, 3B). Western blot analyses confirmed that NF-
κB nuclear/cytoplasmic distribution is unaltered by WFA 
treatment in MDS-L cells (Supplementary Figure 3C), 
indicating that WFA inhibits proliferation of MDS-L cells 
by NF-κB independent mechanism(s).
We utilized gene expression changes induced by 
WFA treatment to query the pathway(s) regulated by 
Figure 2: WFA significantly reduces engraftment of MDS-L cells in the bone marrow of NSGS mice. (A) Representative 
flow cytometry profiles of vehicle or WFA treated mice using the gating scheme illustrated in Supplementary Figure 2B. (B) Average MDS-L 
bone marrow engraftment of 20 mice in the vehicle control group and 27 mice in the WFA group ± SD. * = p<0.05. (C) Representative 
hematoxylin and eosin staining of paraffin-embedded bones from non-engrafted mice or engrafted mice treated with vehicle or 8 mg/kg 
WFA.
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WFA in MDS-L cells, and focused on early time points 
(6 and 12 h) to identify primary gene alterations. Shown 
in Supplementary Figure 4, gene set enrichment analysis 
(GSEA) of differentially expressed genes (fold change 
> 3 and q-value <0.05) between WFA treatment and 
DMSO groups revealed a highly significant enrichment 
in expression of apoptosis-related genes by WFA at both 
6 h (false discovery rate (FDR) q-value = 0.0001; family-
wise error rate (FWER) p-value = 0.0001) and 12 h (FDR 
q-value = 0.0001; FWER = 0.008). So we investigated 
if WFA decreased mitochondrial membrane potential 
(MMP) in MDS-L cells, as it is a well-known indicator 
of apoptosis [27]. MMP was assessed by the widely used 
JC-1 assay, which measures changes in the ratio of JC-1 
mitochondrial aggregates to cytoplasmic monomers [28]. 
Flow cytometric analysis revealed a decrease in JC-1 
Figure 3: Effect of WFA on MMP, CASPASE-3 activation and annexin-V/PI staining in MDS-L cells. (A) The effect of 
WFA treatment (10 μM or 20 μM for 8 h) or FCCP (50 μM for 2 h) on MMP in MDS-L cells was determined by JC-1 assay. The distribution 
of JC-1 aggregates (red) and monomeric JC-1 (green) was analyzed by flow cytometry. Mean ratios ± SD of JC-1 aggregates/monomers 
as a function of treatment (n = 3), where *** = p<0.0005 (left). Representative data from one of multiple experiments (n>3) with similar 
results are shown. Microscopy images showing changes in mitochondrial JC-1 accumulation of MDS-L cells after 8 h of 10 μM WFA 
treatment (right). (B) Immunoblots for total and cleaved CASPASE-3 expression with DMSO or WFA treatment (6 or 12 h) in MDS-L 
cells. Expression normalized to GAPDH is indicated. Results are representative of three experiments. (C) MDS-L cells were treated with 
increasing concentrations of WFA for 48 h and apoptosis assessed by annexin-V/PI staining. Representative flow cytometry profiles by 
WFA concentration (left) and the percentage of annexin-V positive cells at different doses of WFA are presented as mean ± SD (n = 3) 
(right). Data are representative of three independent experiments.
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aggregates with a concomitant increase in JC-1 monomers 
in WFA-treated MDS-L cells compared to DMSO control 
(Supplementary Figure 5), indicating a decrease in 
MMP in MDS-L cells with WFA treatment (Figure 3A). 
Microscopy analysis confirmed that accumulation of JC-1 
aggregates was significantly lower in WFA-treated MDS-L 
cells relative to DMSO treatment (Figure 3A), consistent 
with a decrease in MMP.
During apoptosis, a decline in MMP ultimately 
results in the activation of caspases by proteolytic 
cleavage, a hallmark of apoptosis [27, 29]. Of the known 
human caspases, CASPASE-3 is the most frequently 
activated that commits cells to apoptosis [29]. WFA 
significantly activated CASPASE-3 in MDS-L cells in as 
early as 6 h and the activated protease persisted for at least 
6 more hours (Figure 3B). As expected, we observed a 
simultaneous decrease in total CASPASE-3 (Figure 3B). 
In accordance with the MMP and caspase-3 data, WFA 
caused a dose-dependent increase in annexin-V positive 
apoptotic cells (Figure 3C).
Treatment with WFA activates JNK/AP-1 
signaling in MDS-L cells
We next sought to identify the critical pathway(s) 
mediating the anti-proliferative effects of WFA on MDS-L 
cells. The finding that growth suppression of MDS-L 
cells by WFA involved cell death by apoptosis (Figure 3) 
narrowed our focus to pro-apoptotic signaling pathways 
that involve major WFA-regulated genes in MDS-L cells. 
Figure 4: WFA treatment increased C-JUN/FOSB expression and ROS production in MDS-L cells. (A) qRT-PCR 
analysis of C-JUN (top) and FOSB (bottom) expression in cells treated with DMSO or WFA (6 or 12 h) using human specific primers. 
Gene amplification was normalized to RPII expression and relative amplification was determined by normalizing to DMSO control. ** = 
p<0.005, *** = p<0.0005. Presented data are representative of two independent experiments. (B) Representative flow cytometry profiles 
of ROS production in MDS-L cells by DCFDA fluorescence showing ROS production in MDS-L cells exposed to 10 μM WFA for 30 min 
(top), in the presence or absence of NAC (middle). Amount of ROS produced normalized to DMSO control samples is presented as mean 
± SD (n = 3) (bottom). ** = p<0.005, *** = p<0.0005. Data are representative of three experiments.
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Shown in Supplementary Figure 6 are the top 10 elevated 
and repressed genes identified by microarray analysis, 
arranged according to average fold change. JUN and 
FOSB were among the top 3 up-regulated genes at 6 h 
(47 and 36 fold respectively) and the top 2 up-regulated 
genes at 12 h (52 and 60 fold respectively). C-JUN and 
FOSB heterodimerize to form an AP-1 transcription factor 
that is activated by phosphorylation of the C-JUN subunit 
by JNK, a signaling pathway that has been demonstrated 
to regulate apoptosis [30]. A receptor-mediated event or 
oxidative stress is usually associated with activation of the 
JNK/AP-1 signaling pathway [30]. Since ROS production 
had been implicated in the anti-cancer effects of WFA in 
other systems, we hypothesized that WFA activates ROS-
mediated JNK/AP-1 signaling in MDS-L cells.
qRT-PCR confirmed a robust increase in C-JUN and 
FOSB mRNA in MDS-L cells treated with WFA (Figure 
4A). Next, we investigated if WFA treatment caused any 
change in ROS production in MDS-L cells, since ROS has 
been implicated in activation of JNK and the downstream 
AP-1 pathway [31]. WFA increased ROS accumulation 
in MDS-L cells compared to DMSO as measured by 
increased fluorescence of the ROS sensitive dye, carboxy-
H2DCFDA (Figure 4B). Pretreatment with the ROS 
Figure 5: JNK/AP-1 signaling is activated in WFA-treated MDS-L cells. (A) Phospho and total protein immunoblots for MKK7, 
JNK and C-JUN in WFA-treated (10 μM) MDS-L cells for the indicated time-points. Activated protein expression levels normalized to the 
respective total protein are presented. Data are representative of at least two independent experiments. (B) MDS-L cells co-transfected with 
either an AP-1 or empty firefly luciferase expression vector and a renilla luciferase vector under the control of a constitutive promoter (2:1) 
were treated with WFA (10 μM) or PMA (30 ng/ml) for 12 h and promoter activity was assessed by the dual Glo luciferase assay. Firefly 
luciferase activity relative to renilla luciferase activity is shown as mean ± SD of triplicate cultures. Presented data are representative of 
three independent experiments. (C) BIM (top) and p21 (bottom) mRNA expression was evaluated by qRT-PCR in MDS-L cells treated with 
WFA. Gene amplification was normalized to RPII expression and relative amplification was determined by normalizing to DMSO control. 
** = p<0.005, *** = p<0.0005. Presented data are representative of two experiments.
Oncotarget77443www.impactjournals.com/oncotarget
scavenger, N-acetyl cysteine (NAC), 4 h prior to WFA 
treatment led to complete inhibition of WFA-induced ROS 
(Figure 4B).
The ROS sensitive MAP3K, apoptosis signal-
regulating kinase 1 (ASK1), mediates JNK signaling 
by phosphorylating and activating MKK7 [31, 32]. 
Therefore, we sought to determine the level of MKK7 
phosphorylation in MDS-L cells after WFA treatment. 
WFA increased phosphorylation of MKK7 (Figure 5A). 
MKK7 is a MAP2K known to specifically activate JNK 
[33], which in turn phosphorylates nuclear c-Jun [30]. 
Increased phosphorylation of both JNK and C-JUN was 
observed in WFA-treated MDS-L cells (Figure 5A). The 
fact that C-JUN phosphorylation was only detected at 6 
h compared to JNK phosphorylation, which was detected 
as early as 30 min post-treatment, suggested a sequential 
activation of the signaling cascade. Total C-JUN protein 
levels increased at both 6 and 12 h (Figure 5A) which was 
in agreement with the qRT-PCR results (Figure 4A). These 
results suggest that both the increase in JNK activation and 
C-JUN expression could be contributing to the observed 
increase in C-JUN phosphorylation.
We next investigated the potential functional 
relationship between increased C-JUN phosphorylation 
and the transcriptional activity of AP-1. MDS-L cells 
transfected with either an AP-1 reporter or the empty 
vector expressing firefly luciferase were treated with WFA 
for 12 h, and promoter activity assessed by the dual Glo 
luciferase assay. The increase in C-JUN phosphorylation 
led to an increase in AP-1 activity since WFA-induced 
AP-1 promoter driven luciferase activity in MDS-L cells 
was comparable to phorbol myrsitate acetate (PMA) 
(Figure 5B), the known AP-1 activator [34]. Increase in 
AP-1 transcriptional activity was further demonstrated 
by WFA-induced increase in BIM (BCL2L12) and p21 
mRNA expression (Figure 5C), both of which are bona 
fide AP-1 targets [35, 36].
JNK/AP-1 signaling is a significant mediator in 
apoptosis of MDS-L cells by WFA
To address the importance of JNK signaling in 
WFA-induced apoptosis of MDS-L cells, we employed 
a well-characterized selective covalent JNK inhibitor 
Figure 6: WFA-induced ROS mediates JNK/AP-1 signaling. (A) Western blot analysis of phospho and total C-JUN protein levels 
in MDS-L cells treated with JNK-IN-8. MDS-L were cells treated with WFA for the indicated time-points either with or without pretreatment 
with JNK-IN-8 (10 μM) for 4 h. Phospho-C-JUN expression relative to total C-JUN is presented. (B) Immunoblots of phospho- and total 
protein levels for JNK and C-JUN showing the effect of ROS blockade by a 4 h pretreatment with NAC (25 mM) on WFA-induced JNK 
activation in MDS-L cells at the indicated time points. Phospho-JNK or phospho-C-JUN protein expression is shown normalized to the 
respective total protein. (C) BIM (top) and p21 (bottom) mRNA expression by qRT-PCR in WFA-treated MDS-L cells with or without prior 
JNK inhibition (by 4 h pretreatment with 10 μM JNK-IN-8 or 25 mM NAC). Gene amplification was normalized to RPII expression and 
relative amplification was determined by normalizing to DMSO control. * = p<0.05, ** = p<0.005, *** = p<0.0005.
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[37], JNK-IN-8, and the well-known antioxidant NAC.
JNK-IN-8 pretreatment inhibited WFA-induced C-JUN 
phosphorylation (Figure 6A). Induction of ROS by WFA 
is upstream of JNK activation because NAC pretreatment 
significantly inhibited WFA-induced JNK activation 
(Figure 6B). Moreover, phosphorylation of C-JUN, JNK’s 
downstream target, was also substantially inhibited by 
pretreatment with NAC (Figure 6B). Consequently, there 
was a decrease in AP-1 transcription in MDS-L cells 
pretreated with either JNK-IN-8 or NAC, compared to 
WFA-only treated cells as demonstrated by the significant 
downregulation in transcription of AP-1 targets, BIM 
and p21 (Figure 6C). JNK/AP-1 signaling is important 
for apoptosis of WFA-treated MDS-L cells because 
we observed a substantial decrease in WFA-induced 
CASPASE-3 activation upon pretreatment with JNK-IN-8 
or NAC (Figure 7A).
Off-target effects are always a concern with the use 
of small-molecule inhibitors in biological systems. To 
address this issue, we used another widely used reversible 
ATP-competitive JNK inhibitor, SP600125 [38]. Similar 
results with a second inhibitor would argue against the 
possibility that the phenotype observed with JNK-IN-8 
was due to off-target effects, since SP600125 is likely to 
have a different spectrum of off-targets. As was observed 
with JNK-IN-8, SP600125 also decreased WFA-induced 
JNK activation (Supplementary Figure 7A) and caspase-3 
activation (Supplementary Figure 7B).
Selective killing of MDS-L cells by WFA is 
mediated by ROS
The significant contribution of JNK/AP-1 signaling 
in apoptotic cell death of MDS-L cells was corroborated 
Figure 7: JNK/AP-1 signaling mediates apoptosis in WFA-treated MDS-L cells. (A) Western blot analysis of active 
CASPASE-3 (cleaved CASPASE-3) and GAPDH levels in MDS-L cells treated with WFA for 2, 6 or 12 h, with or without 
JNK blockade by 10 μM JNK-IN-8 (left) or 25 mM NAC (right) pretreatment for 4 h. Cleaved CASPASE-3 expression 
normalized to GAPDH is shown. (B) MDS-L cells with or without inhibitor pretreatment (JNK-IN-8 or NAC for 4 h) were 
treated with WFA (10 μM) for an additional 24 h and stained with annexin-V and PI. Representative flow cytometry profiles 
of annexin-V/PI staining (left). Frequency of annexin-V positive cells are presented as mean ± SD (n = 3) (right). *** = 
p<0.0005. Data from one of two similar experiments are shown.
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by a reduction in annexin-V/PI positive cells upon JNK 
inhibition with JNK-IN-8 in WFA-treated cells (Figure 
7B). Interestingly, NAC pretreatment completely 
protected MDS-L cells from apoptosis triggered by WFA 
treatment (Figure 7B). These results suggest that not 
only is ROS upstream of JNK/AP-1 signaling activation 
(Figure 6), it is the predominant mediator by which WFA 
induced cytotoxicity in MDS-L cells. This suggestion 
was substantiated by the observation that WFA failed to 
increase ROS in normal human primary bone marrow cells 
(Figure 8A) which were resistant to WFA-induced cell 
death (Figure 1C). Induction of oxidative stress therefore, 
likely mediates the selective cytotoxicity of WFA to 
MDS-L cells while sparing normal bone marrow cells in 
vitro and in vivo.
DISCUSSION
The responses to current drug treatments for MDS is 
poor [6–8]. Hence, there is a dire need to investigate new 
therapeutic options. In this study, we demonstrated that 
the plant-derived steroidal lactone isolated from Withania 
somnifera, WFA, is selectively cytotoxic to MDS-L cells 
both in vitro and in vivo. Using gene expression changes 
Figure 8: The role of ROS induction in WFA-mediated apoptosis signaling in MDS. (A) WFA-induced (10 μM, 30 min) ROS 
production in normal human primary bone marrow cells by flow cytometry analysis of DCFDA fluorescence. (B) Model depicting the role 
of ROS in WFA-mediated cytotoxicity to MDS cells via JNK/AP-1 activation. As illustrated, WFA treatment increases ROS which activates 
JNK/AP-1 signaling. Increase in expression of AP-1 target genes leads to direct and indirect activation of apoptosis.
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induced by WFA and systematic biochemical analysis, 
we identified ROS-activated JNK/AP-1 signaling as a 
major pathway through which WFA induces MDS-L 
apoptosis. The efficiency with which NAC prevented 
WFA-induced apoptosis of MDS-L cells and the failure of 
WFA to induce oxidative stress in normal human primary 
bone marrow cells suggest that the molecular mechanism 
mediating selective cytotoxicity of WFA on MDS-L cells 
is associated with induction of ROS. This was supported 
by the observation that WFA does not induce cell death 
in normal human primary bone marrow cells but induces 
apoptosis of MDS patient-derived primary bone marrow 
cells.
For the first time, our studies established a link 
between WFA-induced ROS, JNK/AP-1 signaling and 
apoptosis in MDS-L cells. WFA-induced AP-1 activation 
was demonstrated by an increase in the mRNA expression 
of bona fide AP-1 targets [35, 36], BIM and p21. BIM is 
a crucial apoptosis regulator [39, 40] which induces BAX 
and BAD activation by inhibiting anti-apoptotic proteins 
such as BCL-2 and MCL-1; these activities result in 
increased mitochondrial permeability and apoptosis [41]. 
WFA caused a significant decrease in MMP in MDS-L 
cells. Cell cycle inhibitor, p21, could also contribute to 
WFA-induced apoptosis of MDS-L cells since prolonged 
cell cycle arrest triggers apoptosis [36]. Cell cycle analysis 
by flow cytometry showed WFA did induce MDS-L 
cell arrest at both S and G2/M phases (Supplementary 
Figure 8A). Consistent with these cell cycle analysis 
data, treatment with WFA significantly decreased mRNA 
and protein levels of the cyclins and CDKs required to 
complete both S (cyclin A2, CDK2) and G2/M (cyclin B1, 
CDK1) phases of the cell cycle (Supplementary Figure 8B, 
8C). Apoptosis analyses by both CASPASE-3 expression 
and annexin-V staining revealed JNK/AP-1 signaling to 
be a major pathway activated by increased ROS which 
mediates apoptosis in WFA-treated MDS-L cells. The 
lack of strict correlation between the CASPASE-3 and 
annexin-V assays could be due to lack of binding of the 
inhibitor to newly synthesized JNK protein. This is a 
likely possibility as JNK inhibition by JNK-IN-8 occurs 
via the formation of an irreversible covalent bond with 
a conserved cysteine residue [37], although complete 
gene deletion studies are required for confirmation. Taken 
together, we propose a model by which WFA increases 
ROS in MDS-L cells to induce cell death primarily by 
apoptosis via the JNK/AP-1 pathway (Figure 8B).
Redox homeostasis is an essential albeit delicate 
balance as excess ROS can result in apoptotic cell death 
[31]. Most cancer cells are at a higher oxidative state 
than their normal counterparts [42–44] thus, an increase 
in ROS would therefore push cancer cells beyond the 
toxic threshold [44, 45]. It is known that cancer cells 
adapt to this increased oxidative state by upregulating 
their antioxidant capacity, which decreases their ability to 
regulate further changes in oxidative stress compared to 
normal cells [44, 46]. Upregulation of antioxidants as an 
adaptation to intrinsic oxidative stress is a phenomenon 
that has been demonstrated to be true in MDS [47, 48]. 
The higher oxidative state of cancer cells therefore, 
provides a target for therapeutic selectivity [44]. Several 
studies have demonstrated the potential of exploiting 
redox biology differences between malignant and normal 
cells in discriminately eradicating malignant cells with 
minimum toxicity to normal cells [49]. Although targeting 
redox biology is promising therapeutic strategy, one of 
the challenges is to determine the optimal drug dose that 
pushes malignant but not normal cells beyond the toxic 
threshold. A recent report suggested that a 1 μM dose 
of WFA causes limited apoptosis of MDS-L cells, likely 
due to simultaneous induction of both autophagy and 
apoptosis [50] but our studies demonstrated that a 10 μM 
dose induced robust apoptotic cell death in MDS-L cells. 
The variable outcomes could be due to differences in dose 
or purity of WFA used. Identifying the optimal dose of 
prooxidants is therefore, a critical step for the development 
of such agents as cancer therapeutics.
A major goal in cancer therapy is to develop drugs 
that selectively target malignant cells with minimum 
toxicity to normal cells. The implication of oxidative stress 
in the development and prognosis of MDS [47] suggests 
ROS-inducing agents could eradicate MDS cells. Our 
studies indicate that the growth-suppressive effects of 
WFA on MDS are mediated by prooxidant mechanisms 
that discriminate malignant cells from normal cells. This 
is of particular importance because chemotherapeutic 
drugs generally cause bone marrow suppression which 
leads to treatment delays and significant dose reductions 
[25]. Some MDS patients progress to AML and several 
ROS-inducing agents are cytotoxic to AML cells [4, 49]. 
Interestingly, we found that WFA was effectively cytotoxic 
to both KG1 AML cell line and primary human AML cells 
(Supplementary Figure 9) suggesting it has therapeutic 
potential across the MDS disease progression spectrum, as 
well as in AML. Our finding that the selective cytotoxicity 
of WFA on MDS-L cells is strongly associated with 
induction of ROS, justify targeting oxidative stress as a 
selective therapeutic approach in MDS.
MATERIALS AND METHODS
Reagents
WFA was isolated from Withania somnifera extract 
(Sabinsa Corp) using a series of solvent extractions and 
silica gel-based vacuum liquid column chromatography at 
the University of Louisville and at the laboratory of Dr. I. 
P. Singh, National Institute of Pharmaceutical Education 
Research (NIPER), India. The purity was found to be >94% 
by UPLC. WFA was reconstituted in dimethyl sulfoxide 
(DMSO). Anti-human CD45-PE (12-9459-42) and CD33-
FITC (11-0339-42) were purchased from eBioscience 
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(San Diego, CA). Cremophor (C5135), Carbonyl cyanide 
4-(trifluoromethoxy)phenylhydrazone (FCCP) (C2920), 
hydrogen peroxide (H2O2) (H1009), Phorbol 12-myristate 
13-acetate (PMA) (P1585), N-acetyl-cysteine (NAC) 
(A8199), RNase A (R6513), SP600125 (S5567), JNK-IN-8 
(SML-1246), JC-1 (T4069), HEPES solution (H0887), 
ethylenediaminetetraacetic acid (EDTA) solution (E7889), 
dimethyl sulfoxide (D2438) and monoclonal anti-β-actin 
antibody (A5441) were purchased from MilliporeSigma-
Aldrich (St. Louis, MO). Antibodies to P-p38 (9211S), total 
p38 (9212), cleaved caspase-3 (9661S), total caspase-3 
(9665S), P-MKK7 (4171S), P-c-Jun (9261S), total c-Jun 
(9162), GAPDH (2118S), CDK2 (2546P), cyclin A 
(4656P), CDK1 (9116) and cyclin B (4135) were obtained 
from Cell Signaling Technology (Danvers, Massachusetts). 
Anti-total MKK7 was purchased from Zymed (32-7000). 
Antibodies to Hdac1 (7872), NF-κB p65 (372) P-JNK 
(6254) and total JNK (571) and NF-κB p65 (372) were 
obtained from Santa Cruz Biotechnology (Santa Cruz, 
CA). Peroxidase coupled goat anti-rabbit (SC-2004) and 
anti-mouse (SC-2005) Ig secondary antibodies were also 
acquired from Santa Cruz Biotechnology (Santa Cruz, CA). 
1X phosphate buffered saline (16750-078) was obtained 
from VWR (Radnor, PA). Lenalidomide (NC0600901) 
was purchased from Thermo Fisher Scientific (Waltham, 
MA). Biotin conjugated rat anti-CD45R/B220 (553086), 
anti-CD11b (553309), anti-Gr-1 (553125), anti-CD8α 
(5532029), anti-Ter-119 (553672), anti-CD5 (553019); 
streptavidin APC CY7 (554063) and anti c-KIT-APC 
(553356) were purchased from BD Pharmingen (San 
Diego, CA). Anti-Sca-1-PB (122520) was purchased from 
BioLegend (San Diego, CA).
Cell culture
MDS-L cells were maintained in IMDM/Ham’s 
F-12 (50:50) medium supplemented with 12% fetal bovine 
serum (Atlanta Biologicals), 5 μg/ml apotransferrin, 50 
μM 2-mercaptoethanol (2-ME) and 20 ng/ml of human 
IL-3 (PeproTech). The cell line was authenticated by 
expression of cell surface markers as previously described 
[19]. Human primary bone marrow cells were obtained 
according to Institutional IRB guidelines. Bone marrow 
mononuclear cells were isolated by Ficoll-paque™ plus 
(GE Healthcare) and maintained in RPMI medium 
supplemented with 50 μM 2-mercaptoethanol, 1 μM 
sodium pyruvate and 10% fetal bovine serum (FBS). 
Human primary cells were obtained in accordance with the 
Declaration of Helsinki and approval from the institutional 
review board, protocol # 88-00241. MDS/AML samples 
were obtained from Leukemia Tissue Bank of the Ohio 
State University Comprehensive Cancer Center (OSU 
CCC). MDS/AML cells were thawed and maintained in 
RPMI medium supplemented with 10% fetal bovine serum 
and 10 ng/ml hIL-3, GM-CSF and stem cell factor (R&D 
Systems). All media were purchased from GIBCO-Life 
Technologies.
MTT assay
MDS-L (1.5 × 105) or normal human primary 
bone marrow (1 × 106) cells were treated with increasing 
concentrations of WFA (0 – 20 μM) in 96 well flat-bottom 
microtiter plates for 48 h in 0.2 ml of media. Cells were 
cultured in quadruplicates. Treated cells were incubated 
with 0.5 mg/ml MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide) dye (Sigma Aldrich) for 
4 h followed by solubilization of formazan salt with acidic 
isopropanol and spectrophotometric measurements at 560 
nm and 690 nm. Optical density variation was corrected 
by subtracting OD 690 from OD 560 nm values. Media 
background was subtracted from all treatment groups and 
a DMSO control group was included in each experiment. 
IC50 was computed by Graphpad analysis.
MDS-L xenotransplantation
Animal studies were conducted under an approved 
protocol (# 2011-0904) by the University of Kentucky 
Institutional Animal Care and Use Committee. NOD/
SCID-IL2R γ-hSCF/hGM-CSF/hIL3 (NSGS) mice were 
obtained from The Jackson Laboratories (Bar Harbor, 
ME). 6 -7 month old male and female littermates were 
exposed to 2.5Gy irradiation in a Mark I-68 137Cesium 
γ-irradiator (J.L Shepherd and Associates). Four hours 
later, mice were engrafted by intravenous injection with 
MDS-L cells (1 × 106 cells/mouse).
Mice were treated from day 14 post-engraftment 
with 8 mg/kg of WFA intraperitoneally 5x a week for 
6 weeks. Control mice received vehicle (10% DMSO, 
20% Cremophor-Ethanol (1:3), 70% phosphate PBS). 
MDS-L engraftment was assessed by the percentage of 
human CD45+/CD33+ positive cells in the bone marrow 
compartment. Positively stained cells were detected by the 
BD LSRII flow cytometer and the data was analyzed by 
the FlowJo (Ashland, OR) single cell analysis software.
Bone marrow histology
Bones which had been preserved in formalin (Fisher 
Scientific #SF93-4) were washed with running tap water 
for an hour and decalcified in Richard-Allan scientific 
decalcifying solution (Thermo Scientific #8340) for 
3 h. Decalcified bones were washed, cut horizontally, 
processed, embedded in paraffin, sectioned and routinely 
stained with hematoxylin and eosin. The slides were 
evaluated by a veterinarian blinded to group treatments 
for abnormalities.
Mitochondrial membrane potential by JC-1
MDS-L cells (7.5 × 105 cells/ml) were exposed to 
WFA (10 μM) or DMSO for 8 h. Cells treated with FCCP 
(50 μM) for 2 h were used as a positive control. JC-1 was 
added at a 1 μM final concentration to cells for the last 30 
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min of treatment at 37°C and fluorescence was measured 
by the iCyt Synergy sorter system (Sony Biotechnology 
Inc., San Jose, CA) with 488 and 561 nm lasers. WinList 
3d 8.0 software (Verity Software House Inc., Topsham, 
Maine) was used for data analyses. For microscopy, 
cells treated with WFA (10 μM) or DMSO and stained 
with JC-1 as described above were mounted on poly-l 
Lysine (MilliporeSigma-Aldrich # P-6282) coated slides 
by Cytospin. Pictures were taken on the same day with 
a Nikon A1RSi confocal microscope (Nikon Instruments 
Inc, Melville, NY).
Immunoblotting
MDS-L cells (7.5 × 105 cells/ml) were cultured 
with 10 μM WFA or DMSO for different time points. 
Alternatively, cells were pretreated with JNK-IN-8 (10 
μM) or NAC (25 mM) for 4 h before further treatment with 
WFA (10 μM) for the indicated time points. Cells were 
lysed in Cell Signaling lysis buffer (#9803) containing 
1mM PMSF (Sigma P7626), 2mM NaF (Sigma S-1504), 
2mM Na3VO4 (Sigma S-6508) and 1x protease inhibitor 
cocktail (Roche 5892953001). 35 μg total protein/sample 
of total lysate was subjected to SDS polyacrylamide gel 
electrophoresis. Western blot analysis was performed as 
previously described [51]. Band densitometry analysis 
was performed using the NIH ImageJ program. Protein 
expression was normalized to GAPDH, β-actin or total 
target protein expression as appropriate.
Annexin-V apoptosis assay
The annexin-V apoptosis detection kit (A432) 
from Leinco Technologies (St. Louis, MO) was used for 
annexin-V assays. Thawed human primary MDS/AML 
cells were maintained in culture for 24 h and then treated 
with increasing concentrations of WFA for 24 h. Treated 
cells were stained with annexin-V-FITC and PI following 
the manufacturer’s protocol. Data was acquired with 
the Becton-Dickinson FACSCalibur flow cytometer and 
analyzed with the BD CellQuest™ Pro software (San Jose, 
CA). For MDS-L cells, 7.5 × 105 cells/ml were treated with 
increasing WFA concentrations for 48 h before staining. 
In the case of JNK or ROS inhibition studies, 7.5 × 105 
MDS-L cells/ml after a 4 h JNK-IN-8 (10 μM) or NAC 
(25 mM) pretreatment, or no pretreatment were treated 
with WFA (10 μM) for 24 h and stained with annexin-V/
PI. Stained MDS-L cells were detected by the BD LSRII 
flow cytometer and BD CellQuest™ Pro software was 
used for data analyses.
Affymetrix microarray analyses
10 × 106 MDS-L cells were treated with WFA 
(10 μM) or DMSO for 6 h or 12 h and total RNA was 
extracted using the Direct-zol™ RNA miniprep kit (Zymo 
Research #R2051). RNA purity was assessed using the 
Agilent RNA 6000 Nano assay kit (#5067-1511) on the 
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA). The RNA integrity number (RIN) was ≥ 9 for 
all samples. Sense-strand DNA (ss-cDNA) was generated, 
amplified and biotinylated using the WT Plus Reagent kit 
(Affymetrix, Santa Clara, CA) from 100 ng total RNA 
per sample. 30 μg of fragmented biotin-labelled ss-cDNA 
was hybridized to Affymetrix human gene 2.0 ST arrays 
at 45°C and 60 rpm for 16 h. The arrays were washed, 
stained using the Affymetrix fluidics station FS 450 and 
scanned on the Affymetrix 7G GeneChip Scanner. The raw 
microarray data files were processed through Oligo [52] 
for data extraction and normalization.
Gene expression profiles of MDS-L cells were 
examined in triplicate using Affymetrix human gene 2.0 
ST arrays. Differential expression analyses comparing 
WFA-treated and control groups were performed by 
limma [53]. Significantly up/downregulated genes were 
determined as fold change > 3 and q-value < 0.05. Gene 
set enrichment analysis was performed using GSEA 
software and the Hallmark gene sets in the Molecular 
Signature Database (MSigDB) [54].
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted by TRIzolR reagent 
(LifeTechnologies #15596-018) and cDNA was 
synthesized from 500 ng of total RNA with qScript reverse 
transcriptase (Quanta Biosciences #95048-100). iTaq™ 
universal SYBRR green fluorescent Supermix (Biorad 
#172-5121) was used to quantify mRNA expression. 
RNA polymerase II was used as an internal control. BIO-
RAD CFX Manager software was used to perform relative 
quantification of target genes using the comparative C
T
 
(ΔΔC
T
) method. Primers were obtained from Integrated 
DNA Technologies (IDT, Coralville, Iowa) and the 
sequences are provided in Supplementary Table 1.
ROS measurements
Cell permeant 6-Carboxy-2', 
7'-Dichlorodihydrofluorescein Diacetate (Carboxy-
H2DCFDA) (ThermoFisher Scientific #C400), was used as 
an indicator for intracellular ROS measurement. MDS-L 
cells were treated with DMSO, WFA (10 μM) or H2O2 (1 
mM) for 30 min at 37°C. Alternatively, cells were treated 
with N-acetyl-cysteine (NAC) (25 or 50 mM) for 4 h 
followed by DMSO, WFA (10 μM) or H2O2 (1 mM) for 
additional 30 min at 37°C. Treated cells were suspended 
in warm H2DCFDA solution (1.25 μg/ml in PBS) and 
incubated in the dark at 37°C for 20 min. Fluorescence 
was detected on the BD LSR II flow cytometer and the 
BD CellQuest™ Pro software was used for data analyses. 
The oxidized form of DCFDA, 5-(and-6)-Carboxy-2', 
7'-Dichlorofluorescein Diacetate (Carboxy-DCFDA) 
(ThermoFisher Scientific #C369), was used as a control 
for uptake, cellular esterase activity and decay.
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AP-1 luciferase assay
TK-renilla luciferase vector was a generous gift 
from the laboratory of Dr. Martha Peterson, Department 
of Microbiology, Immunology and Molecular Genetics, 
University of Kentucky, USA. 2.5 × 106 cells were co-
transfected with 20 μg of TK Renilla luciferase vector and 
40 μg of firefly luciferase pGL3 vector (AP-1 or empty 
vector) at 250 mV, 960 μF and 200 Ω in 200 μl of MDS-L 
culture medium with a Gene Pulser electroporator (BIO-
RAD, Hercules, CA). Transfected cells were cultured in 
MDS-L culture medium for 24 h at 8.5 × 105 cells per 
well in 6 well flat bottom plates (Corning #353224). 24 h 
after transfection, 1 × 105 cells per well were treated with 
10 μM WFA or 30 ng/ml PMA for 12 h in white 96 well 
flat bottom polystyrene plates (Corning #3917, Corning 
Incorporated Inc, Durham, NC). Promoter activity was 
assessed by the Dual-Glo® Luciferase assay system 
(Promega #E2920, Promega Corporation, Madison, 
WI). Luminescence was measured using the GloMax® 
Explorer luminometer (Promega). Media background 
luminescence was subtracted and the ratio of firefly to 
renilla luminescence was calculated.
Statistical analysis
Statistically significant differences between groups 
were evaluated by Student’s t test or Tukey’s test for post 
hoc pairwise multiple comparisons as appropriate and 
p values < 0.05 were considered significant. GraphPad 
Prism 6.05 was used for statistical analyses (GraphPad 
Software, Inc., La Jolla, CA).
Additional methods are provided in Supplementary 
Materials.
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